Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stromal Cells for SARS-CoV-2 Pneumonia
NCT05433298Phase 2Withdrawn
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in COVID-19 pneumonia (2 arms). Primary endpoint: Safety of intravenously infused UCT-MSC suspension at 1 year. Planned start May 2022; status: withdrawn.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05433298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05433298.